Wednesday, May 29, 2024
Cartography Biosciences, Inc., has unveiled a new strategic collaboration with Gilead Sciences, Inc., aimed at developing therapies for patients with triple-negative breast cancer (TNBC) and the most common form of non-small cell lung cancer (NSCLC), adenocarcinoma.
This partnership, spanning multiple years, will utilize Cartography’s proprietary computational and genomics platform to identify and validate novel tumor-selective target antigens and pairs of antigens. The company's ATLAS and SUMMIT platforms integrate single-cell data from a comprehensive healthy reference and tumor atlas, employing target identification algorithms to pinpoint single or pairs of targets specific to the intended target cells and optimized for therapeutic programs. Gilead has the option to select multiple targets identified through this collaboration and will handle all further research, development, and commercialization of programs against those targets.
Cartography Biosciences, expressed excitement about the collaboration, stating, “We are thrilled to partner with Gilead to uncover novel and promising antigen targets using our ATLAS and SUMMIT platforms. With the oncology target landscape becoming increasingly crowded, there's an urgent need for innovative, targeted therapies for patients. Cartography eagerly anticipates collaborating with Gilead, drawing upon their oncology expertise and drug development capabilities to identify tumor-specific targets and target pairs that could pave the way for groundbreaking therapies.”
As per the agreement's terms, Cartography will receive an upfront payment of $20 million, along with additional near-term preclinical milestones. The company is also eligible for development, regulatory, and commercial milestones, as well as tiered royalties on net sales for Gilead programs targeting each chosen option.
Source: businesswire.com
